Eagle Pharmaceuticals stock faces October 16 settlement deadline – AD HOC NEWS
A USD 9.5 million cash fund received final approval on August 19, 2026. Eagle Pharmaceuticals stock traded at USD 0.970 on October 6, with a USD 12.6 million market cap.
Eagle Pharmaceuticals stock (ISIN US2697961082) was last at USD 0.970 on OTC Markets on October 6, 2026, giving the company a market capitalization of USD 12.63 million. The central investor event is a USD 9.5 million securities settlement approved on August 19, 2026, with claims due by October 16, 2026, according to OpenClassActions.
The settlement fund covers investors who purchased Eagle common stock between August 9, 2022 and October 1, 2024. The court entered final judgment on August 19, 2026, while the claim window remains open through October 16, 2026, the settlement page states.
Law360 listed the final approval as an August 20, 2026 legal development and described the agreement as a USD 9.5 million investor deal. The settlement resolves claims related to alleged disclosures about Eagle revenue and its Pemfexy product; the defendants denied wrongdoing, according to the settlement account.
Eagle common stock traded on the Nasdaq Global Market during the settlement class period. Nasdaq suspended trading on October 3, 2024, and the stock moved to the OTC Expert Market under the same ticker on October 4, 2024, according to OpenClassActions.
That listing change helps explain the wide market-data spread. On October 6, 2026, the USD 0.970 quote stood 55.91 percent below the USD 2.200 52-week high and above the USD 0.001 52-week low. The same quote page lists Eagle in the healthcare sector and specialty and generic drug manufacturing industry.
Investing.com lists November 9, 2026 as Eagle Pharmaceuticals’ next earnings date. The company describes its portfolio as including products for oncology, central nervous system conditions and critical care, including RYANODEX, BENDEKA, PEMFEXY and BYFAVO, according to its investor page at Eagle Pharmaceuticals.
For investors, the settlement deadline and the OTC trading venue define the immediate framework around EGRX. The USD 12.63 million market capitalization and the 52-week range show a security whose quoted value remains highly sensitive to limited trading liquidity and legal-case developments.
EGRX was last at USD 0.970 on OTC Markets on October 6, 2026. The quote was 55.91 percent below the USD 2.200 52-week high.
More news and analyses on Eagle Pharmaceuticals stock
source
This article was autogenerated from a news feed from CDO TIMES selected high quality news and research sources. There was no editorial review conducted beyond that by CDO TIMES staff. Need help with any of the topics in our articles? Schedule your free CDO TIMES Tech Navigator call today to stay ahead of the curve and gain insider advantages to propel your business!
Eagle Pharmaceuticals stock (ISIN US2697961082) was last at USD 0.970 on OTC Markets on October 6, 2026, giving the company a market capitalization of USD 12.63 million. The central investor event is a USD 9.5 million securities settlement approved on August 19, 2026, with claims due by October 16, 2026, according to OpenClassActions.
The settlement fund covers investors who purchased Eagle common stock between August 9, 2022 and October 1, 2024. The court entered final judgment on August 19, 2026, while the claim window remains open through October 16, 2026, the settlement page states.
Law360 listed the final approval as an August 20, 2026 legal development and described the agreement as a USD 9.5 million investor deal. The settlement resolves claims related to alleged disclosures about Eagle revenue and its Pemfexy product; the defendants denied wrongdoing, according to the settlement account.
Eagle common stock traded on the Nasdaq Global Market during the settlement class period. Nasdaq suspended trading on October 3, 2024, and the stock moved to the OTC Expert Market under the same ticker on October 4, 2024, according to OpenClassActions.
That listing change helps explain the wide market-data spread. On October 6, 2026, the USD 0.970 quote stood 55.91 percent below the USD 2.200 52-week high and above the USD 0.001 52-week low. The same quote page lists Eagle in the healthcare sector and specialty and generic drug manufacturing industry.
Investing.com lists November 9, 2026 as Eagle Pharmaceuticals’ next earnings date. The company describes its portfolio as including products for oncology, central nervous system conditions and critical care, including RYANODEX, BENDEKA, PEMFEXY and BYFAVO, according to its investor page at Eagle Pharmaceuticals.
For investors, the settlement deadline and the OTC trading venue define the immediate framework around EGRX. The USD 12.63 million market capitalization and the 52-week range show a security whose quoted value remains highly sensitive to limited trading liquidity and legal-case developments.
EGRX was last at USD 0.970 on OTC Markets on October 6, 2026. The quote was 55.91 percent below the USD 2.200 52-week high.
More news and analyses on Eagle Pharmaceuticals stock
Disclaimer…
source
This article was autogenerated from a news feed from CDO TIMES selected high quality news and research sources. There was no editorial review conducted beyond that by CDO TIMES staff. Need help with any of the topics in our articles? Schedule your free CDO TIMES Tech Navigator call today to stay ahead of the curve and gain insider advantages to propel your business!
